跳至主要内容
临床试验/NCT07046767
NCT07046767招募中不适用

A Multicenter Hybrid Platform Trial Comparing the Effects of a Prospective Cohort Treated With a Tri- Layer Amnion Graft or a Single Layer Amnion Graft to a Coarsened Exact Matched Retrospective Control Cohort of Patients With Hard-to-heal DFUs and VLUs

Capsicure, LLC14 个研究点 分布在 1 个国家目标入组 165 人开始时间: 2025年10月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
165
试验地点
14
主要终点
Wound Closure

研究概览

简要总结

CAMP RWE Trial: A Multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a tri-layer amnion graft or a single layer amnion graft to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs

详细描述

A multicenter hybrid platform trial comparing the effects of a prospective cohort treated with a tri layer amnion graft or a single layer amnion graft to a coarsened exact matched retrospective control cohort of patients with hard-to-heal DFUs and VLUs

Hybrid prospective platform 2 arm, comparative, randomized multicenter study with a CSM matched retrospective control group Interventional comparative study

  • IP 1: BioLab Membrane Wrap Lite
  • IP2: BioLab Tri-Membrane Wrap

Standard of care: Debridement, maintenance of proper moisture balance, reduction in bacterial burden, offloading and multilayer compression.

Patients with nonhealing venous leg ulcerations or diabetic foot ulcers of at least 4-weeks duration that have failed to show 50% PAR with SOC therapies Patients receiving SOC therapies for hard-to-heal VLUs and/or DFUs

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female 18 years of age and older
  • 2. Subjects having a non-healing venous leg ulcer or diabetic foot ulcer of >4 weeks duration and visible signs of healing objectively, less than 50% reduction in wound size in the last 4 weeks
  • Subjects' wound size is minimum of 2 cm2 and maximum of 25cm2
  • If the subject has more than one eligible wound the largest wound will be selected (the index wound)
  • Subject is able and willing to follow the protocol requirements
  • Subject has signed informed consent

排除标准

  • Inability to adhere to the study protocol or study visit schedule
  • Child-bearing potential without appropriate contraception
  • Treatment of the wound with engineered tissue or other scaffold materials within 30 days preceding the first treatment visit.
  • Visible signs of improvement in the four weeks before randomisation (defined objectively as a 50% reduction in surface area in the four weeks before enrolment)
  • The subject has other concurrent conditions that in the opinion of the investigator may compromise subject safety
  • Known contraindications to the use of amniotic tissue grafts
  • The index ulcer shows clinical signs and symptoms of wound infection needing treatment with local or systemic antimicrobials or antibiotics

结局指标

主要结局

Wound Closure

时间窗: 12 Weeks

To demonstrate the clinical effectiveness of IP1 and IP2 as an adjunct to standard of care in supporting wound healing compared to standard of care alone in venous leg ulcers and diabetic foot ulcers across the continuum of care. Thus, the incidence of index ulcers obtaining complete wound closure by 12 weeks will be collected.

次要结局

  • Wound percent area reduction(Weeks 4, 8, and 12)

研究者

申办方类型
Network
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验